Why we need pharmaceutical solutions? You be the judge

[Sequoiacrone]

http://www.dynamicalertlimited.com/

Now here is an HONEST company stating their goals and research for cannabis pharmaceuticals.
We see these companies patenting medicines and here is one that is at least forthcoming about those goals.

If cancer can be cured or prevented by cannabis products, then why shouldn't they be able to profit from it. Not everyone is capable of growing their own medicine.

The almost 10 minute video with Money TV interview was very interesting.

Here is the blurb for it...
October 24, 2008 President & CEO Richard Cowan and Director & Chief Science Officer Robert Melamede, Ph.D. spoke with anchor Donald Baillargeon of MoneyTV about the benefits of medical marijuana and the company's phytocannabinoid pharmaceuticals.


Personally I have no problems with commercial products that will WORK, but the point is will they have a problem with ME growing and making my own medicines. It works for me NOW.

[Sequoiacrone]

Pharmaceutical Drugs Based on Cannabis

Pharmaceutical drugs have been developed which either contain or have similar chemicals as those found in the marijuana (cannabis) plant. Some researchers have used their understanding of how the brain processes cannabinoids (http://medicalmarijuana.procon.org/viewresource.asp?resourceID=161#cannabinoid) to develop drugs which follow the same pathways but work differently than marijuana. Pharmaceutical drugs based on marijuana are divided into four categories and listed below with the names, trade names, manufacturers, approval status, suggested medical use and cannabis-related properties. All drugs referenced are in pill form unless otherwise noted.

Drugs that contain chemicals taken directly from the marijuana plant (http://medicalmarijuana.procon.org/viewresource.asp?resourceID=883#direct)
Drugs that contain synthetic versions of chemicals naturally found in marijuana (http://medicalmarijuana.procon.org/viewresource.asp?resourceID=883#copy)
Drugs that contain chemicals similar to those in marijuana but not found in the plant (http://medicalmarijuana.procon.org/viewresource.asp?resourceID=883#synthetic)
Drugs that do not work like marijuana but use the same brain pathways (http://medicalmarijuana.procon.org/viewresource.asp?resourceID=883#brainpath)
For the entire article see here
http://medicalmarijuana.procon.org/viewresource.asp?resourceID=883

[Sequoiacrone]

Cannasat Therapeutics Inc. announces NRC-IRAP funding for CAT 210 12 February 2007 Cannasat Therapeutics Inc. is pleased to announce a contribution agreement with the National Research Council Canada Industrial Research Assistance Program ("NRC-IRAP") for pre-clinical research and development of CAT 210. CAT 210 is Cannasat's second product in development that targets the treatment of neuropathic pain (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1740) with cannabinoids. Pre-clinical studies for CAT 210 will be conducted at the Pain Centre at the McGill University Health Centre (MUHC). Early stage formulation work for CAT 210 will take place at the Cannasat's R&D facilities in Edmonton, Canada.
"We are very pleased to be sharing the costs of this project with NRC-IRAP for development of CAT 210 as part of our R&D efforts in developing novel cannabinoid drug products. Development of CAT 210 expands our pipeline of cannabinoid-based pharmaceuticals for neuropathic pain, a condition for which there is a large underserved market. We are also very excited to be working with the Pain Centre at McGill, one of the world's leading institutions in pain research," states David Hill, Chief Executive Officer of Cannasat Therapeutics.
Neuropathic pain arises from injury to the peripheral or central nervous system and is associated with trauma or diseases such as diabetes, herpes zoster, HIV/AIDS, and multiple sclerosis. Affecting approximately 26 million people worldwide, neuropathic pain is one of the most difficult forms of pain to treat - only 50 per cent of patients respond to current treatment options. As such, there is a large unmet need for new therapies.
ABOUT CANNASAT THERAPEUTICS INC.
Cannasat Therapeutics is researching the therapeutic benefits of cannabis and developing new cannabinoid pharmaceutical products. Cannasat is pursuing two complementary business strategies. The first consists of development of novel cannabinoid-based pharmaceutical products through application of drug delivery technologies to be introduced to the market through the traditional regulatory drug approval process. The second is to promote medicinal cannabis research and education with Cannasat's business partner, Prairie Plant Systems Inc., the only government licensed grower and distributor of medicinal cannabis in Canada.
Source: Cannasat Therapeutics Inc.

[Sequoiacrone]

Posted March 30, 2009
(MarijuanaNews note from Richard Cowan: The second time is “the charm.” Last year, we tried to do a similar deal, but it fell through as a result of the market crash. I am really looking forward to working with Steve Kubby and Dr. Robert Melamede in building a patient-oriented medical cannabis research company. There will be more announcements soon.
As one might guess, working on this merger has taken up so much of my time that I have not been able to write about the issues and opportunities confronting the cannabis reform movements. I hope that I can get back to writing soon.)
From: http://finance.yahoo.com/news/GULF-Acquires-Assets-of-bw-14778413.html
GULF Acquires Assets of Cannex Therapeutics LLC
Will Develop Medical Cannabis Pharmaceutical Products
Monday March 30, 2009, 3:10 am EDT
ADDISON, Texas–(BUSINESS WIRE)–Gulf Onshore Inc (OTCBB: GFON.OB - News) announced today that it has acquired the assets of Cannex Therapeutics and will continue development of its medical cannabis-based pharmaceutical products. Cannex Therapeutics is a privately owned California group founded and operated by Medical Cannabis pioneer and entrepreneur Steven W. Kubby (www.kubby.com). The asset purchase agreement includes all intellectual property rights, formulas, patents, trademarks, client base, hardware and software pertaining to Cannex’s pharmaceutical cannabis research & development business.
Along with the Cannex asset purchase the Company has appointed Steve W. Kubby as President & CEO, Richard Cowan as Director & CFO, and Robert Melamede Ph. D., as Director & Chief Science Officer. The Company believes that the combination of this team and the assets purchased positions the Company at the top of the Medical Cannabis Industry. World renowned individually in the medical cannabis community, this management team brings real-world experience to the research & development of medical cannabis-based pharmaceutical products.
About Steven W. Kubby, President & CEO
Mr. Kubby, the founder of Cannex, is an entrepreneur with a wide range of experience and success in businesses ranging from property management to publishing to political fundraising. He received his BA in Psychobiology from California State University and holds a lifetime teaching credential. Mr. Kubby is a long-term survivor, for more than three decades, of a rare form of adrenal cancer with a mortality prognosis of 6-12 months. Leading specialists in the US and Canada have confirmed that his survival is due to medical cannabis. Mr. Kubby is the executive director of the American Medical Marijuana Association, an internationally recognized organization comprised of doctors, lawyers, nurses and patients working for the rights of medical cannabis patients primarily in the United States and Canada. Mr. Kubby played a key role in the drafting and passing of California’s historic medical cannabis initiative (Proposition 215) in 1996. He has also authored two books on drug policy reform. As a widely recognized medical marijuana pioneer and political leader, Mr. Kubby is intimately familiar with the legal and regulatory problems involved in developing and marketing cannabinoid-based pharmaceuticals.
About Dr. Robert J. Melamede, Director & Chief Science Officer
World-renowned Medical Cannabis Research expert Dr. Robert Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. Dr. Melamede is a retired Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach and research cannabinoids, cancer, and DNA repair. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede’s current focus is on integrating far from equilibrium thermodynamic physics with the biology of life and health and the unique evolutionary role played by the endocannabinoid system in these processes. Dr. Melamede also serves on the Editorial Board of The Journal of the International Association for Cannabis as Medicine, the Scientific Advisory Board of Americans for Safe Access, Sensible Colorado, Scientific Advisor for Cannabis Therapeutics as well as a variety other of state dispensaries and marijuana patient advocacy groups. Dr. Melamede frequently serves as an expert witness in cannabis-related trials. Dr. Melamede’s testimony was critical in the recent trial of growers for the Vancouver Island Compassion Society that resulted Canadian Court’s ruling that their current medical marijuana laws were unconstitutional. Please visit www.phytiva.com andwww.youtube.com to view speeches by Dr. Robert Melamede speaking on the effectiveness of Medical Cannabinoids on for a number of different medical applications.
About Richard Cowan, Director & CFO
Mr. Richard Cowan has a Bachelor of Arts in Economics from Yale University. He has served on the board of several public companies as a specialist in mergers and acquisitions with a focus on corporate finance. Mr. Cowan is a former CEO of the National Organization for the Reform of Marijuana Laws (NORML) Mr. Cowan has had national media coverage for several topics including writings on National Review Cover Article “Why Conservatives Should Support the Legalization of Marijuana”. In his book Smoke and Mirrors, Dan Baum...
READ ALL...


http://marijuananews.com/blog/general-news/kubby-melamede-and-cowan-take-medical-cannabis-research-company-public-via-%E2%80%9Creverse-merger/